WuXi Pharmatech Inc. ADR buy klostergang
Zusammenfassung
Diese Einschätzung wurde am 07.12.15 mit einem Endkurs von 41,69 € beendet. Die BUY Einschätzung von klostergang zeigte mit einer Rendite von 8,33 % einen positiven Trend. klostergang hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| WuXi Pharmatech Inc. ADR | - | - | - | - |
| iShares Core DAX® | 4,09 % | 4,89 % | 17,42 % | 22,41 % |
| iShares Nasdaq 100 | 1,42 % | -0,45 % | 37,62 % | 58,20 % |
| iShares Nikkei 225® | -1,57 % | -4,91 % | 12,95 % | 7,96 % |
| iShares S&P 500 | 1,82 % | 0,78 % | 29,18 % | 49,91 % |
Kommentare von klostergang zu dieser Einschätzung
In der Diskussion WuXi Pharmatech Inc. ADR diskutieren
WuXi PharmaTech
Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use.
30.10.2015: Gilead Sciences (NASDAQ:GILD) and WuXi PharmaTech (NYSE:WX) establish a strategic partnership to conduct analytical and stability studies of small molecule new chemical entities to support global marketing applications and commercial products.